DEEJ(000423) 国金证券·2025-03-31 10:23Investment Rating - The report assigns an "Accumulate" rating to the company for 2025 with a target price of 68.57 RMB based on a 24x PE ratio [4]. Core Views - The company demonstrates robust growth in its core business, particularly in the Ejiao segment, supported by strong brand barriers and refined inventory management. The company is expected to achieve a double-digit growth in Ejiao blocks in 2024, with a projected net profit of approximately 1.56 billion RMB, reflecting a year-on-year increase of 35.3% [2][4]. - The report highlights the rapid growth of the Compound Ejiao Syrup, which has significant room for penetration in both retail and medical channels. The retail sales of this product are expected to reach 2.32 billion RMB in 2024, up 14.8% year-on-year [2][4]. Summary by Sections Company Overview - Dong-E Ejiao Co., Ltd. is a leading producer of Ejiao and related products, with a history of over 70 years. The company has established itself as a top brand in the health supplement market, with a strong focus on product innovation and market expansion [13][14]. Business Performance - The company has seen a recovery in net profit since 2021, with a projected revenue of approximately 5.92 billion RMB in 2024, representing a year-on-year growth of 25.6%. The compound annual growth rate (CAGR) for revenue from 2021 to 2024 is estimated at 15% [24][4]. - The company has successfully improved its inventory management, which has positively impacted its financial performance. The net profit for 2024 is expected to be around 1.56 billion RMB, showing a significant recovery trend [24][4]. Product Growth and Innovation - The report emphasizes the dual growth strategy of the company, focusing on both pharmaceutical and consumer products. The Ejiao block remains a strong performer, while the Compound Ejiao Syrup is rapidly gaining market share [30][55]. - New product lines such as the "Peach Blossom Princess" Ejiao cake and Ejiao powder are expected to contribute to revenue growth, with projected increases of over 10% and 75% respectively in 2024 [63][66]. Financial Health - The company maintains a healthy financial position with a cash reserve exceeding 8.5 billion RMB and a low debt ratio of 21.1%. The dividend payout ratio has consistently exceeded 96% from 2021 to 2024, with a projected dividend yield of 3.85% in 2024 [18][4]. - The report forecasts steady revenue growth for the next few years, with expected revenues of 6.89 billion RMB, 7.99 billion RMB, and 9.22 billion RMB for 2025, 2026, and 2027 respectively, alongside corresponding net profits [4][7].